This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.2 | Special Copayment Reduction: V117 | Special Copayment Reduction period: 5 years |
| B. Synonyms | Glucosylceramide Lipidosis, Glucocerebrosidosis, GBA-related lysosomal storage disease |
| C. Adult onset | High likelihood of first onset in adulthood — many cases of type 1 (non-neuronopathic) Gaucher disease are first diagnosed in adulthood, and some are found in old age. |
| 1. History | 1882: described by Gaucher; 1965: enzyme deficiency confirmed; 1991: world's first ERT approved |
| 2. Causes | GBA gene mutation → glucocerebrosidase deficiency → accumulation of glucosylceramide in macrophages |
| 3. Genetics | Autosomal recessive, GBA (1q22), major variants such as N370S and L444P, founder effect in Ashkenazi Jews |
| 4. Epidemiology | Most common lysosomal storage disease, general population 1:40,000–60,000; Ashkenazi Jews 1:850 |
| 5. Pathophysiology | Accumulation of glucosylceramide in macrophage lysosomes → formation of Gaucher cells → organ infiltration |
| 6. Symptoms | Type 1: hepatosplenomegaly, cytopenia, bone lesions; Type 2: acute neurological involvement; Type 3: chronic neurological involvement |
| 7. Signs | Hepatosplenomegaly, pancytopenia, reduced bone density, bone marrow infiltration, elevated chitotriosidase |
| 8. Screening | DBS glucocerebrosidase enzyme activity; included in newborn screening in some countries |
| 9. Diagnosis | Reduced leukocyte enzyme activity + GBA gene analysis + plasma glucosylsphingosine measurement |
| 10. Treatment | ERT (imiglucerase, velaglucerase, taliglucerase) and SRT (miglustat, eliglustat) |
| 11. Prognosis | Type 1: normal survival can be expected with ERT; Type 2: early death; Type 3: survival for decades after neurological progression |
| 12. Prevention | Genetic counseling, carrier testing (especially Ashkenazi Jews), PGT, prenatal diagnosis |
| 13. References | Gaucher PCE. De l'epithelioma primitif de la rate and 9 other papers |
Gaucher disease first appeared in the medical literature in 1882, when the French medical student Philippe Charles Ernest Gaucher described in his doctoral thesis the autopsy findings of a 51-year-old female patient with a markedly enlarged spleen. Gaucher observed unusual large cells in the patient's spleen and misinterpreted them as a primary epithelioma of the spleen. Later, in 1907, Brill and colleagues showed that Gaucher cells were not a simple epithelioma, and in the 1920s the disease began to be recognized as a storage disease associated with abnormal lipid metabolism.
In 1934, Aghion identified the substance accumulating in the abnormal cells as a cerebroside, and this substance was later confirmed to be glucosylceramide (glucocerebroside). In 1965, Brady and colleagues discovered that the activity of glucocerebrosidase (β-glucosidase), the enzyme that degrades glucocerebroside, was markedly reduced in spleen tissue from patients with Gaucher disease. This was the decisive discovery establishing Gaucher disease as a lysosomal storage disease.
In 1973, Brady's research team attempted early enzyme replacement therapy by administering glucocerebrosidase extracted and purified from bovine spleen to patients with Gaucher disease. Subsequently, methods of producing clinically usable enzyme were improved, and in 1991 the human placenta-derived enzyme alglucerase (Ceredase®) received FDA approval, becoming the first enzyme replacement therapy among lysosomal storage diseases. In 1994, imiglucerase (Cerezyme®), recombinantly produced in Chinese hamster ovary (CHO) cells, replaced alglucerase. Since then, various ERT preparations and substrate reduction therapy (SRT) drugs have been developed, and more than 5 approved therapies are currently available. The GBA gene was cloned by Sorge and colleagues in 1988.
The cause of Gaucher disease is functional deficiency of the lysosomal enzyme glucocerebrosidase (acid β-glucosidase, GBA1) due to pathogenic variants in the GBA gene. Glucocerebrosidase catalyzes the hydrolysis of glucosylceramide (glucocerebroside) into glucose and ceramide in the acidic environment of the lysosome. Deficiency of this enzyme causes glucosylceramide and its lyso form, glucosylsphingosine (lyso-Gb1), to accumulate progressively within lysosomes, mainly in cells of the mononuclear phagocyte system, especially tissue macrophages.
Glucosylceramide is a component of the cell membranes of blood cells such as erythrocytes and leukocytes, and large amounts of glucosylceramide are generated when aged blood cells are phagocytosed and processed by macrophages of the spleen, liver and bone marrow. In the state of glucocerebrosidase deficiency, this substrate cannot be degraded, and macrophages are transformed into characteristic lipid-laden macrophages called Gaucher cells, which accumulate. Glucosylsphingosine shows much stronger cytotoxicity than glucosylceramide and is currently understood to exert toxicity particularly in the nervous system, causing the neurological involvement of types 2 and 3. Gaucher cells accumulate mainly in the spleen, liver, bone marrow and brain (in the neuronopathic forms).
Gaucher disease is inherited in an autosomal recessive manner. The causative gene, GBA, is located on chromosome 1q22. A factor that complicates GBA gene analysis is that a pseudogene (GBAP) with about 96% sequence homology to GBA lies adjacent at the 1q22 locus, so general NGS panel testing can produce false positives by misidentifying GBAP as GBA, and specialized molecular genetic testing is therefore required.
More than 500 pathogenic GBA variants have been reported to date. The most important variants are N370S (c.1226A>G) and L444P (c.1448T>C). N370S is the most common variant in the Ashkenazi Jewish population and is associated with the type 1 (non-neuronopathic) phenotype without neurological involvement. L444P tends to be associated with the neuronopathic forms (type 2 or 3). In the genotype–phenotype correlation, carrying at least one N370S variant is characterized by the absence of neurological involvement. L444P/L444P homozygosity is associated with type 3 (chronic neuronopathic form). However, clinical phenotypes show considerable heterogeneity even with the same genotype. GBA heterozygous carriers are known to have an increased risk of Parkinson disease, and this association has made GBA an important gene in neuroscience research.
Gaucher disease is the most common of all lysosomal storage diseases, with an incidence of about 1 per 40,000–60,000 births in the general population. The total number of patients with Gaucher disease worldwide is estimated at about 10,000–25,000. A markedly high frequency due to a founder effect is reported particularly in the Ashkenazi Jewish (Eastern European Jewish) population, in which the incidence is about 1:850 and the carrier frequency reaches about 1:15.
By clinical type, type 1 (non-neuronopathic, Type 1) accounts for about 90–95% of all patients with Gaucher disease, and in the Ashkenazi Jewish population almost all cases are type 1. Type 2 (acute neuronopathic, Type 2) is rare worldwide, and type 3 (chronic neuronopathic, Type 3) has been reported at a relatively high frequency in the population of the Norbottnian region of Sweden. In Korea, a small number of patients with Gaucher disease are registered, mainly type 1, and some type 3 patients have also been reported. The incidence is the same in males and females.
The pathophysiology of Gaucher disease begins with lysosomal accumulation of glucosylceramide in tissue macrophages due to glucocerebrosidase deficiency. When blood cells such as erythrocytes and leukocytes age, they are phagocytosed and processed by tissue macrophages of the spleen, liver and bone marrow, and in this process large amounts of glucosylceramide, a cell membrane component, must be degraded. In the state of glucocerebrosidase deficiency, this glucosylceramide cannot be degraded and accumulates within macrophage lysosomes, forming 'Gaucher cells' with large, characteristic intracytoplasmic lipid vacuoles. On electron microscopy, inclusions resembling wrinkled tissue paper or crumpled silk are characteristic.
When Gaucher cells accumulate in the spleen, liver and bone marrow, the following develop: ① pancytopenia due to splenomegaly (hypersplenism), ② hepatomegaly, ③ bone complications such as reduced bone density, bone infarction, pathological fractures and avascular necrosis due to infiltration of the bone marrow by Gaucher cells. Glucosylsphingosine (lyso-Gb1) is strongly neurotoxic, and when it accumulates in the brain it causes neuronal death, neuroinflammation and neurodegeneration, and is understood to drive the pathophysiology of the neuronopathic forms (types 2 and 3). In addition, Gaucher cells secrete various inflammatory cytokines and chemokines, causing a chronic systemic inflammatory response, which is associated with various systemic complications observed in patients with Gaucher disease, such as fatigue, cachexia and increased risk of Parkinson disease.
Gaucher disease is classified into 3 types according to the presence of neurological involvement and age at onset. Type 1 (non-neuronopathic, Type 1, Non-neuronopathic) is the most common type and has no neurological involvement. Symptoms mainly consist of splenomegaly, hepatomegaly, hematological abnormalities (anemia, bleeding tendency due to thrombocytopenia) and bone lesions. Age at onset varies widely from childhood to old age, and some patients are first diagnosed in adulthood or later. Bone lesions present in various ways, including chronic bone pain, bone crisis (acute febrile, excruciating bone pain), bone infarction, avascular necrosis and osteoporosis.
Type 2 (acute neuronopathic, Type 2, Acute Neuronopathic) is a severe neuronopathic form presenting in the neonatal period or early infancy. Retroflexion of the neck (retroflex neck), strabismus, bulbar palsy, spasticity and seizures are characteristic, and non-neurological symptoms (hepatosplenomegaly, growth failure) also accompany it. Most patients die of respiratory failure before age 2. Type 3 (chronic neuronopathic, Type 3, Chronic Neuronopathic) is a neuronopathic form with onset in childhood or adolescence, in which horizontal oculomotor apraxia, seizures, cerebellar ataxia, cognitive decline and spasticity appear gradually. It progresses slowly over decades.
On physical examination, splenomegaly is observed in nearly all type 1 and type 3 patients, and hepatomegaly is also commonly present. The spleen may enlarge to dozens of times its normal size. Blood tests show anemia (low hemoglobin), thrombocytopenia (increased platelet destruction due to hypersplenism) and mild to moderate leukopenia. For bone lesions, plain radiographs show the Erlenmeyer flask deformity (flask-shaped deformity) of the distal femur, cortical thinning and sclerotic/lytic lesions, and MRI is excellent for assessing the degree of Gaucher cell infiltration in the bone marrow.
Serum chitotriosidase activity is elevated tens to hundreds of times in Gaucher disease, and it is the most widely used Gaucher disease biomarker. CCL18 (chemokine ligand 18) and glucosylsphingosine (lyso-Gb1, lysoGb1) are also biomarkers used to monitor Gaucher disease activity and treatment response. Bone density (DEXA) testing confirms reduced bone density. Findings of Gaucher cell infiltration in the liver on liver MRI (low T1 signal intensity), or PAS-positive large macrophages (Gaucher cells) on liver biopsy, support the diagnosis. In type 2 patients, neurological examination reveals oculomotor abnormalities, spasticity and seizures.
Newborn screening for Gaucher disease has been introduced in some countries and regions. Israel performs newborn screening on the basis of the high frequency in the Ashkenazi Jewish population and the availability of effective treatments. Some US states also include Gaucher disease in expanded lysosomal storage disease screening panels. As a screening method, glucocerebrosidase enzyme activity is measured on dried blood spots (DBS) using a fluorescent substrate (4-methylumbelliferyl-β-D-glucopyranoside) or a mass spectrometry-based substrate.
When reduced enzyme activity is found on screening, confirmation is made by GBA gene analysis and precise enzyme activity testing. Plasma glucosylsphingosine (lyso-Gb1) concentration is specifically elevated in patients with Gaucher disease; it is increased in type 1 as well but is even more markedly elevated in the neuronopathic forms (types 2 and 3). Lyso-Gb1 can also be measured on DBS and is used as a second-tier screening biomarker. Carrier screening is recommended before pregnancy or in early pregnancy, particularly in the Ashkenazi Jewish population, and is performed with GBA gene panel testing (including at least the major variants such as N370S and L444P).
Confirmation of Gaucher disease is based on ① biochemical enzyme activity testing and ② molecular genetic testing. Biochemical confirmation consists of demonstrating that glucocerebrosidase enzyme activity in peripheral blood leukocytes or DBS is reduced to less than 15–30% of normal. Molecular genetic confirmation consists of identifying pathogenic variants on both alleles of the GBA gene. Because of the high homology between GBA and the GBAP pseudogene, conventional PCR-based testing may produce errors, so GBA/GBAP-specific primers and precise analytical methods are required.
Gaucher disease is clinically suspected when a combination of ① unexplained splenomegaly, ② pancytopenia, ③ bone pain or bone crisis, and ④ hepatomegaly is present. Serum chitotriosidase and plasma lyso-Gb1 measurements are used as strong supporting biomarkers of Gaucher disease. Identification of Gaucher cells on bone marrow biopsy supports the diagnosis, but because enzyme activity measurement is more specific, the diagnosis should not be confirmed by bone marrow biopsy alone. Differential diagnoses include other lysosomal storage diseases (Niemann-Pick disease, Wolman disease), hematological malignancies (lymphoma, leukemia) and splenomegaly due to infectious causes. To differentiate the neuronopathic forms, horizontal eye movement testing (saccade testing), brain MRI and electroencephalography may be needed.
Gaucher disease is the lysosomal storage disease with the richest treatment options. Currently approved therapies include three intravenous enzyme replacement therapies (ERT) and two oral substrate reduction therapies (SRT). Enzyme replacement therapy (ERT) works by intravenously administering recombinant glucocerebrosidase, which degrades the substrate within macrophage lysosomes. Available ERT preparations include imiglucerase (Cerezyme®), velaglucerase alfa (VPRIV®) and taliglucerase alfa (Elelyso®), all administered intravenously every 2 weeks.
Approved substrate reduction therapies (SRT) are miglustat (Zavesca®) and eliglustat (Cerdelga®). Both drugs act by inhibiting glucosylceramide synthase, reducing substrate production. Eliglustat is an oral drug showing efficacy similar to ERT in adult patients with type 1 Gaucher disease, and dose adjustment according to CYP2D6 metabolizer phenotype is required. Both ERT and SRT are effective for the non-neurological manifestations of type 1 Gaucher disease (splenomegaly, hepatomegaly, cytopenia, bone lesions), but because they cannot cross the blood-brain barrier, they are ineffective against neurological progression in types 2 and 3. New therapeutic strategies, including gene therapy (AAV- and lentiviral vector-based) and molecular chaperone therapy, are currently being actively studied.
In type 1 Gaucher disease, when non-neurological manifestations are effectively managed through early diagnosis and ERT or SRT treatment, normal or near-normal life expectancy can be expected in most patients. Decades of clinical data have confirmed that in type 1 patients receiving regular treatment, splenomegaly, hepatomegaly and cytopenia improve significantly and the incidence of bone complications decreases. However, bone lesions that have already developed before the start of treatment (avascular necrosis, bone deformity, etc.) often do not fully recover even after treatment.
In type 2 Gaucher disease, most patients die of respiratory failure or neurological complications within 2–4 years of birth regardless of treatment, and the effect of current treatment is very limited. In type 3 Gaucher disease, ERT improves non-neurological symptoms but neurological symptoms progress, and patients experience gradual neurological decline over decades. An increased risk of Parkinson disease has been reported in patients with Gaucher disease types 1 and 3 compared with heterozygous GBA carriers, so long-term monitoring is important.
Because Gaucher disease is an autosomal recessive genetic disease, when both parents are heterozygous carriers of a pathogenic GBA variant, each pregnancy has a 25% chance of an affected child. In particular, because the carrier frequency is very high (about 1:15) in the Ashkenazi Jewish population, systematic carrier screening including the GBA gene before pregnancy or in early pregnancy is strongly recommended in this population. Israel operates a national carrier screening program.
Prenatal diagnosis is possible by measuring glucocerebrosidase enzyme activity and analyzing the GBA gene in samples obtained by CVS (10–12 weeks of gestation) or amniocentesis (16–18 weeks of gestation). Preimplantation genetic diagnosis (PGT) is a method of screening embryos for GBA variants after in vitro fertilization and transferring unaffected embryos, and is effective in preventing the birth of an affected child particularly in high-risk couples in which both parents are carriers. It is important to systematically perform carrier testing of the patient's first- and second-degree relatives through cascade testing. Because an increased risk of Parkinson disease is known in heterozygous GBA carriers, carriers should also be informed during counseling of the importance of long-term neurological monitoring.